ALBUQUERQUE, Sept. 7, 2005 (PRIMEZONE) -- Cell Robotics International, Inc (Pink Sheets:CRII) is pleased to announce the addition of the distinguished Dr. Lawrence Madoff to its Board of Directors.
Dr. Madoff graduated from New York University's undergraduate school where he majored in biology and was a researcher in blood disorders. He attended medical school in Geneva, Switzerland where he interned in medical microbiology. Subsequently, Dr. Madoff completed residency training in Hawaii and California. Serving as medical officer with the U.S. Army during the Vietnam War, Dr. Madoff was honorably discharged with the rank of Major. Being currently licensed in four states, his access to numerous contacts and disciplines is expected to be a significant benefit to the company. Dr. Madoff he served in the 1970s with the U.S. Peace Corps as regional physician in the Republic of Cameroon, Africa, and he is fluent in several foreign languages.
Oton Tisch, Chairman of the Board of Cell Robotics International, stated, "We are honored with Dr. Madoff's decision to join our Board of Directors and contribute his expertise in building our management team to penetrate the lucrative Biotech equipment market."
He further stated, "The timing of Dr. Madoff's arrival is excellent since we are now ready to make a major launch of the marketing of our 'Clinical Lasette' product line into the Biotech market following our successful completion of FDA approvals, test marketing, and field trials."
The Clinical Lasette is the only laser-based solution in this market and has significant competitive advantages over the older "lancet"-based technology, including a "needle-less" method of obtaining blood samples, which satisfies the safety rules imposed by the U.S. Congress and OSHA. The estimated size of the world wide market for the Clinical Lasette is over 40 million dollars per annum. Further information on Cell Robotics International, Inc. and its product lines can be obtained on its website at www.cellrobotics.com
This press release contains "forward-looking statements" within the meaning of Private Securities Litigation Reform Act of 1995. Such statements can be identified by lead-in "Looking Forward." These statements are not guarantees of future performance and involve significant risks and uncertainties. Actual results may vary materially from those in the forward-looking statements as a result of the effectiveness of management's strategies and decisions, general economic and business conditions, new or modified statutory or regulatory requirements, and changing price and market conditions.